Design Therapeutics
DSGN
95 hedge funds and large institutions have $108M invested in Design Therapeutics in 2024 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 27 reducing their positions, and 13 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 27
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
2.42% more ownership
Funds ownership: 54.39% → 56.81% (+2.4%)
2% more funds holding
Funds holding: 93 → 95 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less capital invested
Capital invested by funds: $124M → $108M (-$16.4M)
93% less call options, than puts
Call options by funds: $5K | Put options by funds: $75K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$4.66M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.55M |
| 3 |
AC
Almitas Capital
Santa Monica,
California
|
+$885K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$700K |
| 5 |
Millennium Management
New York
|
+$492K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.22M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$1.78M |
| 3 |
Walleye Capital
New York
|
-$523K |
| 4 |
SC
Shay Capital
New York
|
-$517K |
| 5 |
Morgan Stanley
New York
|
-$345K |
DSGN Hedge Fund Activity: Q2 2024 in Review
95 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q2 2024, worth a combined $108M — down 13% from $124M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new DSGN positions and 13 closed out — a net gain of 2 holders — while 36 added to existing stakes and 27 trimmed.
The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $4.66M. The largest seller was Citadel Advisors, cutting an estimated $2.22M.
- 95 institutional investors held Design Therapeutics (DSGN) as of Q2 2024, up from 93 in Q1 2024.
- Funds reported $108M of Design Therapeutics stock for Q2 2024, down 13% quarter-over-quarter.
- 15 funds opened new Design Therapeutics positions in Q2 2024 and 13 closed out, a net change of +2 holders.
- The largest Design Therapeutics buyer in Q2 2024 was Frazier Life Sciences Management, an estimated $4.66M added.
- The largest Design Therapeutics seller in Q2 2024 was Citadel Advisors, an estimated $2.22M sold.
Based on aggregated 13F filings for Q2 2024.